Albert David Ltd

Albert David Limited: Trading Window closed from 1 October 2026; will open 48 (forty-eight) hours after declaration of the Unaudited Financial Results for the period ended 30th September, 2026.

AGM Details

• 87th AGM held on 6 August 2026 at 09:30 IST via VC/OAVM.
• Minutes of the AGM submitted to exchanges.

AGM Details

• AGM held on Aug 6, 2026 at 9:30 AM via VC/OAVM.
• Scrutinizer appointed: CS Ashok Kumar Daga.
• Voting rights cut-off date: 30 July 2026.
• Remote e-voting: Aug 3–5, 2026; AGM voting concluded Aug 6.
• All resolutions 1–7 passed by requisite majority.

Key Resolutions

• Item 1: Adopt Audited financial statements and reports; Ordinary.
• Item 2: Declare dividend of Rs 5 per equity share.
• Item 3: Re-appoint director retiring by rotation.
• Item 4: Ratify cost auditor remuneration for 2026-27; Rs 70,000 plus taxes and expenses.
• Item 5: Special: revise remuneration for Executive Chairman for 2026-27; minimum remuneration; Schedule V.
• Item 6: Regularize Additional Director Amit Mahla as Director.
• Item 7: Special: appoint Amit Mahla as Whole-time Director & CEO for five years; remuneration terms per agreement.

Dividend

• Dividend approved: Rs 5 per equity share.

Director Changes

• Amit Mahla regularized as Director; liable to retire by rotation.
• Amit Mahla appointed as Whole-time Director & CEO for five-year term.

Auditors

• Cost Auditor remuneration ratified for 2026-27: Rs 70,000 plus taxes and expenses.

Material Related Party Transactions

• Votes by interested parties excluded from counting; no material RPT approved.

Other Material Approvals

• All resolutions passed; no other material approvals reported.

AGM details

• AGM held on 6 August 2026 at 09:30 IST via VC/OAVM.
• Voting cut-off date was 30 July 2026; remote e-voting Aug 3–5, 2026.
• Meeting concluded at 10:43 IST.

Ordinary Business

• Adoption of audited financial statements and reports (ordinary).
• Dividend of Rs 5 per equity share declared.
• Re-appointment of Ms. Prabhawati Devi Kothari by rotation.

Special/Other resolutions

• Ratification of remuneration of Cost Auditors for FY 2026-27.
• Remuneration revision for Executive Chairman for 2026-27.
• Regularisation of Amit Mahla as Director.
• Appointment of Amit Mahla as Whole-time Director & CEO for five years; 2026-27 remuneration.

Voting results

• Consolidated voting results to be announced and posted on the company website.

AGM details

• AGM held on 6 August 2026 at 09:30 IST via VC/OAVM.
• Mode: VC/OAVM.
• Voting cut-off date: 30 July 2026.

Key resolutions

• Adoption of audited financial statements and boards and auditors reports (Ordinary).
• Dividend declaration: Rs 5 per equity share (Ordinary).
• Re-appointment of Prabhawati Devi Kothari (retiring by rotation).
• Ratification of cost auditors remuneration for 2026-27 (Ordinary).
• Remuneration revision for Whole-time Director Executive Chairman for 2026-27 (Special).
• Regularisation of Amit Mahla as Director (Ordinary).
• Appointment of Amit Mahla as WTD and CEO for 5 years; remuneration through Mar 2027 (Special).

Voting results

• Voting results pending; consolidated results to be announced and posted online.

Dividends

• Dividend per share: Rs 5.

Directors

• Prabhawati Devi Kothari re-appointed (retiring by rotation).
• Amit Mahla regularised as Director.
• Amit Mahla appointed WTD and CEO for 5 years.

Auditors

• Remuneration of Cost Auditors for 2026-27 ratified.

Other material approvals

• Remuneration approvals and CEO appointment are main items; no ESOPs mentioned.

Resignation of Head- R&D

• Resignation of Senior Managerial Personnel: Dr. Kuntal Ganguly, Head-R&D, effective 5 Aug 2026, due to personal reasons.

Financial results and audit

• Unaudited results for quarter ended 30 June 2026 approved by Board; Audit Committee endorsed.
• Limited Review Report by LBJha & Co LLP indicates no material misstatement.
• Statutory Auditors issued unmodified review report on the quarter.
• Company operates in a single pharmaceutical segment.
• Notes confirm June 30, 2026 results; March 31, 2026 figures are balancing.
• No board changes, dividends, or capital actions disclosed.

Financial results

• Unaudited quarterly results for quarter ended June 30, 2026 approved by the Board.
• Independent Auditor's Limited Review Report on the results attached as Annexure A.
• Audit Committee reviewed and recommended the financial results.